Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Lupus Science & Medicine|October 11, 2022
Changes in cardiorespiratory function and fatigue following 12 weeks of exercise training in women with systemic lupus erythematosus: a pilot studySarfaraz Hasni, Li Rebekah Feng, Marquis Chapman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 1, 2024
The Aconitate Decarboxylase 1/Itaconate Pathway Modulates Immune Dysregulation and Associates with Cardiovascular Disease Markers and Disease Activity in Systemic Lupus ErythematosusEduardo Patiño-Martinez, Shuichiro Nakabo, Kan Jiang, et al.
Medrxiv : the Preprint Server for Health Sciences|September 4, 2023
Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren's DiseaseSarthak Gupta, Eiko Yamada, Hiroyuki Nakamura, et al.
Annals of the Rheumatic Diseases|March 25, 2024
Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren's diseaseSarthak Gupta, Eiko Yamada, Hiroyuki Nakamura, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 24, 2026
Multi-omic profiling reveals immune cell priming signature linked to lupus prognosisMichael A Smith, Dominic Sinibaldi, Saifur Rahman, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 2020
Sex differences in neutrophil biology modulate response to type I interferons and immunometabolismSarthak Gupta, Shuichiro Nakabo, Luz P Blanco, et al.
JCI Insight|April 20, 2018
Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupusPhilip M Carlucci, Monica M Purmalek, Amit K Dey, et al.
Annals of the Rheumatic Diseases|August 1, 2022
Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosusSarfaraz Hasni, Yenealem Temesgen-Oyelakin, Michael Davis, et al.
Nature Communications|June 8, 2021
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosusSarfaraz A Hasni, Sarthak Gupta, Michael Davis, et al.
The Journal of Rheumatology|February 1, 2026
Genome-Wide Association Study Identifies Genetic Loci for Antibody Response to SARS-CoV-2 Vaccines in Patients With Systemic Autoimmune Diseases and Healthy IndividualsKwangwoo Kim, Dillon Claybaugh, Eduardo Patino-Martinez, et al.
Pageof 9